- BIIB +0.83%
Search results
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while ...
- 205.00Add to watchlist+1.68 (+0.83%)At close: Fri. Aug 23, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open204.50High205.54Low202.13
- Mkt Cap29.86BP/E (TTM)25.85Div & YieldN/A & N/A
- Prev. Close203.3252 Wk. Low189.4452 Wk. High270.50
What analysts are sayingTop storiesBiogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend ReimbursementYahoo Finance · 3 days ago- BIIB +0.83%
Eisai’s Leqembi deemed too costly for NHSYahoo Finance · 3 days agoTop 20 biopharmas’ market cap up 4.3% in Q2 2024 as GLP-1 drug innovators hold top spotsYahoo Finance · 5 days agoRelated stocks
Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease.
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan ...
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
Breaking New Ground With Science. With a strong focus on difficult-to-treat diseases, our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients and protect public health.
Jun 7, 2021 · Key Points. The FDA approved Biogen’s Alzheimer’s disease drug aducanumab. It’s the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and ...
Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose pf serving humanity through science while ...